Previously Unachievable Drug Discovery Insights Created by Cardea Bio's BPU Platform

Cardea Bio, a Serra Capital II company, announced this week that it had reached a pivotal milestone, with its first external partner beginning the use of the BPU (Biosignal Processing Unit) platform. This platform is essential in the advancement of drug discovery research and will produce new and highly sought-after insights.

Cardea’s focus is creating products and applications that enable precision healthcare by improving diagnostic ease, speed, and cost. It is the first company to combine expertise in biology, nanotechnology, surface chemistry, engineering, and manufacturing to create practical and scaleable graphene biological field effect transistor (BioFET) products.

To view the complete article, follow here.